Mind Medicine resumed with an Outperform at Oppenheimer

Oppenheimer analyst Jay Olson resumed coverage of Mind Medicine (MNMD) with an Outperform rating and $25 price target The firm previously had no rating on the shares. The analyst has “high conviction” that the company’s lead asset MM120 will “revolutionize” neuropsychiatry with its potential to drive durable remission. MM120 has a “unique” clinical profile with its less-intense but longer psychedelic experience compared to other approaches, the analyst tells investors in a research note.